105 results
8-K
EX-99.1
OCUL
Ocular Therapeutix Inc
7 May 24
Ocular Therapeutix™ Reports First Quarter 2024 Results
4:10pm
, and collaboration revenue.
Research and development expenses for the first quarter of 2024 were $20.7 million versus $14.7 million for the comparable period …
Collaboration revenue
Total revenue, net
Costs and operating expenses:
Cost of product revenue
Research and development
Selling and marketing
General
S-3ASR
9me f5ms0xg7wd
25 Mar 24
Automatic shelf registration
4:40pm
8-K
EX-99.1
5lilv9
11 Mar 24
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results
4:10pm
424B5
wxl os6gn4zofmcs4
14 Dec 23
Prospectus supplement for primary offering
4:09pm
424B5
256o9zznruestn
13 Dec 23
Prospectus supplement for primary offering
4:10pm
8-K
EX-99.1
le5j8daegkzqqtd
7 Nov 23
Ocular Therapeutix™ Provides Third Quarter 2023 Financial Results and Corporate Update
4:04pm
8-K
EX-99.1
e1t8c wifa3azg
7 Aug 23
Ocular Therapeutix™ Provides Second Quarter 2023 Financial Results and Corporate Update
4:06pm
8-K
EX-99.1
zs96r 19pix
8 May 23
Ocular Therapeutix™ Provides First Quarter 2023 Financial Results and Corporate Update
4:04pm